12/5
07:00 am
ntra
Natera Acquires Foresight Diagnostics
Low
Report
Natera Acquires Foresight Diagnostics
12/3
08:00 am
ntra
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
Low
Report
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
12/2
08:00 am
ntra
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
Low
Report
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
12/1
06:03 pm
ntra
Natera (NASDAQ:NTRA) was given a new $265.00 price target on by analysts at Morgan Stanley.
Low
Report
Natera (NASDAQ:NTRA) was given a new $265.00 price target on by analysts at Morgan Stanley.
11/25
10:22 am
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $240.00 to $250.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $240.00 to $250.00. They now have an "overweight" rating on the stock.
11/19
08:00 am
ntra
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
Low
Report
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
11/18
01:59 pm
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at UBS Group AG from $218.00 to $280.00. They now have a "buy" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at UBS Group AG from $218.00 to $280.00. They now have a "buy" rating on the stock.
11/14
08:22 am
ntra
Does Natera (NTRA) Have a Long Runway For Growth? [Yahoo! Finance]
Low
Report
Does Natera (NTRA) Have a Long Runway For Growth? [Yahoo! Finance]
11/13
09:36 am
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Stephens from $197.00 to $235.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Stephens from $197.00 to $235.00. They now have an "overweight" rating on the stock.
11/12
08:00 am
ntra
Natera Integrates with Flatiron Health’s OncoEMR® Platform
Low
Report
Natera Integrates with Flatiron Health’s OncoEMR® Platform
11/11
12:21 pm
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Morgan Stanley from $195.00 to $220.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Morgan Stanley from $195.00 to $220.00. They now have an "overweight" rating on the stock.
11/11
12:21 pm
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Piper Sandler from $220.00 to $230.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Piper Sandler from $220.00 to $230.00. They now have an "overweight" rating on the stock.
11/9
12:53 am
ntra
Natera (NTRA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Natera (NTRA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/7
04:56 pm
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $200.00 to $250.00. They now have a "buy" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $200.00 to $250.00. They now have a "buy" rating on the stock.
11/7
03:46 pm
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $210.00 to $240.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $210.00 to $240.00. They now have an "overweight" rating on the stock.
11/7
02:22 pm
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Wells Fargo & Company from $175.00 to $190.00. They now have an "equal weight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Wells Fargo & Company from $175.00 to $190.00. They now have an "equal weight" rating on the stock.
11/7
11:09 am
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Barclays PLC from $210.00 to $230.00. They now have an "overweight" rating on the stock.
Medium
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Barclays PLC from $210.00 to $230.00. They now have an "overweight" rating on the stock.
11/7
10:27 am
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Evercore ISI from $190.00 to $250.00. They now have an "outperform" rating on the stock.
Medium
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Evercore ISI from $190.00 to $250.00. They now have an "outperform" rating on the stock.
11/7
08:07 am
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at BTIG Research from $210.00 to $230.00. They now have a "buy" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at BTIG Research from $210.00 to $230.00. They now have a "buy" rating on the stock.
11/7
12:20 am
ntra
Natera Inc (NTRA) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions [Yahoo! Finance]
Low
Report
Natera Inc (NTRA) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions [Yahoo! Finance]
11/6
04:05 pm
ntra
Natera Reports Third Quarter 2025 Financial Results
Low
Report
Natera Reports Third Quarter 2025 Financial Results
10/31
07:00 am
ntra
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
Low
Report
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
10/30
07:00 am
ntra
Natera to Report its Third Quarter Results on November 6, 2025
Low
Report
Natera to Report its Third Quarter Results on November 6, 2025
10/28
07:00 am
ntra
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
Low
Report
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
10/27
10:07 am
ntra
Natera (NASDAQ:NTRA) was upgraded by analysts at BNP Paribas to a "neutral" rating.
Low
Report
Natera (NASDAQ:NTRA) was upgraded by analysts at BNP Paribas to a "neutral" rating.